Brief: Inozyme Pharma Reports Positive Topline Data From Ongoing Phase 1/2 Trials Of Inz-701

Inozyme Pharma

16/02/2023 12:35

Feb 16 (Reuters) - Inozyme Pharma Inc  INZY.O :
    * INOZYME PHARMA REPORTS POSITIVE TOPLINE DATA FROM ONGOING
PHASE
1/2 TRIALS OF INZ-701
    * INOZYME PHARMA INC - INZ-701 WAS GENERALLY WELL-TOLERATED
AND
EXHIBITED A FAVORABLE SAFETY PROFILE IN BOTH TRIALS
    * INOZYME PHARMA INC - COMPANY UPDATES ITS CASH RUNWAY
GUIDANCE TO
FUND CASH FLOW REQUIREMENTS INTO Q4 OF 2024
    * INOZYME PHARMA INC - REPORTED ENCOURAGING PATIENT REPORTED
OUTCOME DATA AS MEASURED BY GLOBAL IMPRESSION OF CHANGE (GIC) IN
ENPP1 DEFICIENCY TRIAL
    * INOZYME PHARMA INC - NO SERIOUS OR SEVERE ADVERSE EVENTS
ATTRIBUTED TO INZ-701 AND NO ADVERSE EVENTS LEADING TO STUDY
WITHDRAWAL
    * INOZYME PHARMA INC - EXPECTS TO REPORT CASH, CASH
EQUIVALENTS,
AND SHORT-TERM INVESTMENTS OF APPROXIMATELY $127.9 MILLION AS OF
DECEMBER 31, 2022

Source text for Eikon:  ID:nGNXR3mwg 
Further company coverage:  INZY.O 
 ((Reuters.Briefs@thomsonreuters.com;;))